Dibotatug clinical trials
Also written DR-01.
How each study uses dibotatug is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the dibotatug studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- DR-01
- 3
Studies by the year they started
4 studies that test it; most in 2022 (1)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Dren Bio (4)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test dibotatug.
- Dec 2026A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic LymphomasPhase 1/2 · Dren Bio
- May 2027A Study of DR-01 in Subjects With Alopecia Areata and VitiligoPhase 1 · Dren Bio
Studies
Open first, then newest update. How each study uses dibotatug is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure SyndromesRecruitingPhase 1/2Dren BioNCT07712562Written as Dibotatug (DR-01)
- A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic LymphomasRecruitingPhase 1/2Dren BioNCT05475925Written as DR-01
- A Study of DR-01 in Subjects With Alopecia Areata and VitiligoActive, not recruitingPhase 1Dren BioNCT06602232Written as DR-01
- A Study of Subcutaneous DR-01 in Healthy VolunteersCompletedPhase 1Dren BioNCT06766864Written as DR-01
Codes
What other systems call dibotatug · ClinicalTrials.gg INT016768
- UNII (FDA) HBU6X8D6VBDIBOTATUGOne source FDA
- NCI Thesaurus C190114DibotatugOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | HBU6X8D6VB | DIBOTATUG | One source FDA |
| NCI Thesaurus | C190114 | Dibotatug | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.